TY - JOUR AU - Thomas, Gregory AU - Frederick, Elizabeth AU - Thompson, Lisa AU - Bar-Or, Raphael AU - Mulugeta, Yetti AU - Hausburg, Melissa AU - Roshon, Michael AU - Mains, Charles AU - Bar-Or, David PY - 2020 DA - 2020/11/30 TI - LMWF5A suppresses cytokine release by modulating select inflammatory transcription factor activity in stimulated PBMC JO - Journal of Translational Medicine SP - 452 VL - 18 IS - 1 AB - Dysregulation of transcription and cytokine expression has been implicated in the pathogenesis of a variety inflammatory diseases. The resulting imbalance between inflammatory and resolving transcriptional programs can cause an overabundance of pro-inflammatory, classically activated macrophage type 1 (M1) and/or helper T cell type 1 (Th1) products, such as IFNγ, TNFα, IL1-β, and IL12, that prevent immune switching to resolution and healing. The low molecular weight fraction of human serum albumin (LMWF5A) is a novel biologic drug that is currently under clinical investigation for the treatment of osteoarthritis and the hyper-inflammatory response associated with COVID-19. This study aims to elucidate transcriptional mechanisms of action involved with the ability of LMWF5A to reduce pro-inflammatory cytokine release. SN - 1479-5876 UR - https://doi.org/10.1186/s12967-020-02626-z DO - 10.1186/s12967-020-02626-z ID - Thomas2020 ER -